M. Idzko (Wien, Austria), J. Virchow (Rostock, Germany)
Plasma protein profiles as markers of asthma severity and exposure to oral corticosteroids in U-BIOPRED and BIOAIR
M. Mikus (Stockholm, Sweden), J. Kolmert (Stockholm, Sweden), A. James (Stockholm, Sweden), L. Andersson (Stockholm, Sweden), J. Östling (Mölndal, Sweden), C. Gomez (Stockholm, Sweden), R. Knowles (Stevenage, United Kingdom), B. Dahlén (Stockholm, Sweden), R. Djukanovic (Southampton, United Kingdom), I. Adcock (London, United Kingdom), P. Nilsson (Stockholm, Sweden), S. Dahlén (Stockholm, Sweden)
|     |
Anti-IL-5 therapy and the airway microbiome in asthma.
A. Sullivan (Cork, Ireland), C. Ward (Newcastle upon Tyne, United Kingdom), D. Casey (Cork, Ireland), D. Flynn (Cork, Ireland), E. Hunt (Cork, Ireland), J. Eustace (Cork, Ireland), P. O' Byrne (Hamilton, Ontario, Canada), B. Plant (Cork, Ireland), J. Macsharry (Cork, Ireland), D. Murphy (Cork, Ireland)
| |
Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial
E. Bel (Amsterdam, Netherlands), W. Moore (Winston-Salem, NC, United States of America), O. Kornmann (Frankfurt, Germany), C. Poirier (Montreal, QC, Canada), N. Kaneko (Kamogawa, Japan), S. Smith (Research Triangle Park, NC, United States of America), N. Martin (Brentford, Middlesex and Leicester, United Kingdom), M. Gilson (Uxbridge, Middlesex, United Kingdom), R. Price (Stevenage, Hertfordshire, United Kingdom), E. Bradford (Research Triangle Park, NC, United States of America), M. Humbert (Paris, France)
| |
Clinical trial: Impact of Probiotical® on asthma control and inflammation
C. Moermans (Liege, Belgium), S. Graff (Liege, Belgium), L. Medard (Liege, Belgium), F. Schleich (Liege, Belgium), V. Paulus (Liege, Belgium), F. Guissard (Liege, Belgium), M. Henket (Liege, Belgium), R. Louis (Liege, Belgium)
| |
Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function
J. Maspero (Buenos Aires, Argentina), D. Halpin (Exeter, United Kingdom), D. Jackson (London, United Kingdom), N. Hanania (Houston, United States of America), M. Castro (Kansas City, United States of America), C. Domingo (Barcelona, Spain), N. Daizadeh (Cambridge, United States of America), M. Djandji (Cambridge, United States of America), P. Rowe (Bridgewater, United States of America), Y. Deniz (Tarrytown, United States of America)
| |
CD6-ALCAM Pathway is Elevated in Patients with Severe Asthma
M. Mukherjee (Hamilton, ON, Canada), N. Zhao (Hamilton, ON, Canada), K. Radford (Hamilton, ON, Canada), S. Gatto (San Diego, CA, United States of America), A. Pavlicek (San Diego, CA, United States of America), J. Ampudia (La Jolla, CA, United States of America), C. Ng (La Jolla, CA, United States of America), S. Connelly (La Jolla, CA, United States of America), P. Nair (Hamilton, ON, Canada)
| |
The impact of anti-IgE treatment on the airway microbiome in asthma.
A. Sullivan (Cork, Ireland), C. Ward (Newcastle upon Tyne, United Kingdom), D. Casey (Cork, Ireland), D. Flynn (Cork, Ireland), E. Hunt (Cork, Ireland), J. Eustace (Cork, Ireland), P. O' Byrne (Hamilton, Ontario, Canada), B. Plant (Cork, Ireland), J. Macsharry (Cork, Ireland), D. Murphy (Cork, Ireland)
| |